Home » Pharmacology » Enzymes » Proteases » Matrix Metalloprotease » CP 471474

CP 471474

Cat. No. 3780

Price and Availability

For CP 471474 pricing & availability please select your country from the drop down menu:
Submit

By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: 2-[[[4-(4-Fluorophenoxy)phenyl]sulfonyl]amino]-N-hydroxy-2-methylpropanamide

Biological Activity

Broad spectrum MMP inhibitor (IC₅₀ values are 0.7, 0.9, 13, 16 and 1170 nM for MMP-2, MMP-13, MMP-9, MMP-3 and MMP-1 respectively). Attenuates early left ventricular dilation after experimental myocardial infarction in mice.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Technical Data

M.Wt:

368.38

Formula:

C₁₆H₁₆FN₂O₅S

Solubility:

Soluble to 100 mM in DMSO

Purity:

>97 %

Storage:

Store at -20°C

CAS No:

210755-45-6

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch

Safety Data Sheet: View Safety Data Sheet

References

Rohde et al (1999) Matrix metalloproteinease inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99 3063. PMID: 10368126.

Lindsey et al (2002) Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 105 753. PMID: 11839633.

Fang et al (2007) Differences in inflammation, MMP activation and collagen damage account for gender difference in murine cardiac rupture following myocardial infarction. J.Mol.Cell.Cardiol. 43 535. PMID: 17689559.

If you know of a relevant citation for this product please let us know.